Table 2.
Disease-Free Survival Hazard Ratios for MPO Genotypes Among Women in Treated and Untreated Arms Controlling for Menopausal Status, Time Between Surgery and Registration, and Type of Randomized Treatment
| Treatment and MPO Genotype | Total No. of Patients | Failures | Adjusted HR | 95% CI | P |
|---|---|---|---|---|---|
| CAF or CMF | |||||
| AA, referent | 22 | 11 | 1.00 | ||
| AG | 120 | 36 | 0.53 | 0.27 to 1.05 | .07 |
| GG | 259 | 65 | 0.41 | 0.22 to 0.78 | .007 |
| CAF or CMF with no adjuvant therapy | |||||
| AA, referent | 26 | 7 | 1.00 | ||
| AG | 246 | 77 | 1.27 | 0.59 to 2.76 | .54 |
| GG | 481 | 131 | 1.08 | 0.50 to 2.31 | .84 |
| Treated with CAF or CMF plus tamoxifen | |||||
| AA, referent | 12 | 7 | 1.00 | ||
| AG | 66 | 17 | 0.28 | 0.12 to 0.69 | < .01 |
| GG | 115 | 22 | 0.19 | 0.08 to 0.45 | < .000 |
| Treated with CAF or CMF with no tamoxifen | |||||
| AA, referent | 10 | 4 | 1.00 | ||
| AG | 54 | 19 | 0.92 | 0.31 to 2.71 | .88 |
| GG | 144 | 43 | 0.76 | 0.27 to 2.12 | .60 |
Abbreviations: MPO, myeloperoxidase; HR, hazard ratio; CAF, cyclophosphamide, doxorubicin, and fluorouracil; CMF, cyclophosphamide, methotrexate, and fluorouracil.